Cancer Antigen 19-9（CA19-9）CLIA Kit

Chemiluminescence Immunoassay for the quantitative determination of Cancer Antigen 19-9（CA19-9）CLIA Kitin human serum

REF SKT-057 CE IVD 100, 150 +2 +8 °C

INTENDED USE

Cancer Antigen 19-9 (CA19-9) CLIA Kit is a Chemiluminescence Immunoassay (CLIA) intended for the quantitative measurement of human cancer antigen 19-9 (CA19-9) in serum.

For in-vitro diagnostics purposes only

SUMMARY OF PHYSIOLOGY

CA19-9 is detected using the 1116-NS-19-9 monoclonal antibody. The reaction site of 1116-NS-19-9 is located on a glycolipid molecule with a molecular weight of about 10,000 Da. This mucin resembles the haptens of the Lewis blood group family and is a component of mucosal cells.[1] About 3-7% have a Lewis a-negative/b-negative blood group structure that does not express similar such mucins of CA19-9.
Therefore, care must be taken when interpreting the results. Mucin is secreted by fetal gastric, intestinal, and pancreatic epithelial cells.
Low concentrations of mucin are also found in adult liver, lung, and pancreatic tissue.[2,3]
The detection value of CA19-9 can help in the differential diagnosis and monitoring of pancreatic cancer patients (sensitivity reaches 70-87%).[4]There is no correlation between the size of the tumor and the detection value of CA19-9, but almost all patients with serum CA19-9 level over 10000U/mL had distant metastasis of the tumor. CA19-9 cannot be used as an early detection indicator for pancreatic cancer. The sensitivity for cholangio carcinoma CA19-9 is approximately 50-75%. For gastric cancer, simultaneous detection of CA72-4 and CEA is recommended. Only CEA testing is recommended for colon cancer; CA 19-9 testing is only valuable in rare CEA-negative cases.
Since mucin is secreted by the liver, mild cholestasis can lead to a marked increase in serum CA19-9 levels. Benign lesions or inflammation of the gastrointestinal tract and liver can also lead to elevated CA19-9 levels, such as cystic fibrosis. [5,6]

ASSAY PRINCIPLE

The Cancer Antigen 19-9（CA19-9）CLIA Kit is designed, developed, and produced for the quantitative measurement of human CA19-9 level in serum samples. The assay utilizes a two-site “sandwich” technique with two antibodies that bind to different epitopes of CA19-9.
Assay calibrators, controls, or patient serum samples are added directly to a reaction vessel together with acridinium ester magnetic particles and biotinylated anti-CA19-9 polyclonal antibody. The magnetic particles capture the biotin antibody as well as an immunocomplex in the form of “magnetic particles–biotin CA19-9 antibody–streptavidin coated CA19-9–CA19-9 antibody”. Materials bound to the solid beads are held in a magnetic field while unbound materials are washed away. Then, trigger solutions are added to the reaction vessel and light emission is measured with the ECL100 analyzer. The relative light units (RLU) are *proportional* to the concentration of a CA19-9 in the sample. The amount of analyte in the sample is determined from a stored, multi-point calibration curve and reported in serum CA19-9 concentration.

REAGENTS: PREPARATION AND STORAGE

This test kit must be stored at 2℃~8℃ upon receipt. For the expiration date of the kit refer to the label on the kit box. All components are stable until this expiration date. It can be stored for 1 month at 2℃~8℃ after kit opening.

1. CA19-9 Magnetic Particle Solution (05701)
Qty: 11.0mL (100/kit),16.0mL (150/kit)
Storage: 2 – 8°C
Preparation: Ready to Use

2.Biotin CA19-9 antibody (05702)
Qty: 6.0mL (100/kit),8.5mL (150/kit)
Storage: 2 – 8°C
Preparation: Ready to Use

3. Acridinium ester Streptavidin (05703)
Qty: 6.0mL (100/kit),8.5mL (150/kit)
Storage: 2 – 8°C
Preparation: Ready to Use

4.CA19-9 Calibrators (05706-05708)
Qty: 3 x vials
Storage: 2 – 8°C
Preparation: Ready to Use
After the first use, it is recommended to storage at 2 - 8℃ and can be used within one month. Do not freeze.

5.CA19-9 Controls(05709-05710)
Qty: 2 x vials
Storage: 2 – 8°C
Preparation: Ready to Use
After the first use, it is recommended to storage at 2 - 8℃ and can be used within one month. Do not freeze.

SAFETY PRECAUTIONS

The reagents must be used in a professional laboratory environment and are for in vitro diagnostic use. Source material which contains reagents of bovine serum albumin was derived in New Zealand. It was obtained only from healthy donor animals maintained under veterinary supervision and found free of contagious diseases. Wear gloves while performing this assay and handle these reagents as if they were potentially infectious. Avoid contact with reagents containing hydrogen peroxide. Do not get in eyes, on skin, or on clothing. Do not ingest or inhale fumes. On contact, flush with copious amounts of water for at least 15 minutes. Exercise Good Laboratory Practices.

MATERIALS REQUIRED BUT NOT PROVIDED

1. ECL100 Immunoassay Analyzer (ECL100) or ECL25 Immunoassay Analyzer (ECL25)
2. EDI™ Cuvettes (CL011)
3. EDI™ Wash Reagent (P-594)
4. EDI™ Trigger Solutions A and B (P-595A, P-595B)

The instrument must operate using materials supplied by Epitope Biotechnology, Co.,Ltd. or Epitope Diagnostics, Inc. When materials are sourced from third-party suppliers are

being used, Epitope Biotechnology, Co.,Ltd. and Epitope Diagnostics, Inc. takes no responsibility of the validity for obtained results. Materials are available to purchase from Epitope Biotechnology, Co.,Ltd. and Epitope Diagnostics, Inc. Please contact your distributor for more information.

SPECIMEN COLLECTION AND PREPARATION

1. Blood sample should be collected under sterile conditions.
2. For human serum samples only; other body fluids and samples may not yield accurate results.
3. Clinical samples shall be tested within 2 hours after collection. ;If the measurement cannot be completed within 2 hours, please store the following way:
   - Store at low temperature and away from light (2℃~8℃) for 2 days.
   - Store at -20℃ or below for up to 6 months.
   - Freeze and thaw only once.
4. Avoid heating inactivated samples, mixed, contaminated and hemolysis samples should be discarded.
5. Samples should be restored to room temperature before testing. Samples stored in freezer should be completely melted, and mixed evenly before use. Due to possible volatilization, samples, calibrators and controls on the ECL platform should be tested within 2 hours.
6. Some substances in the samples will interfere with the test results. The common interfering substances and maximum allowable concentrations are as follows:
   - bilirubin: 66 mg/dL
   - triglyceride: 1500 mg/dL
   - hemoglobin: 2200 mg/dL
   - biotin: 400 nmol/L
   - For patients receiving high-dose biotin therapy (5 mg/day), samples must be collected 8 hours after intaking the last dose of biotin.
7. A single assay of this item requires 10 µL of sample. This quantity does not include the amount of dead volume in the sample container, the capacity required for retesting, and other measurement items. For the definition of minimum required sample size, refer to the equipment manual.

CALIBRATION

An active calibration curve is required for all tests. For the assay, calibration is required for the first time use of a reagent lot and every 14 days thereafter or when either kit control is out of range. Refer to appropriate system manuals for configuring calibrators.

QUALITY CONTROL

The characteristics of patient samples are simulated through controls and are critical to validate the performance of CLIA assays due to the random access format. Use of controls is left to the discretion of the user, based on good laboratory practices, requirements, and applicable laws. We suggest performing a control test once every day. Quality control results that do not fall within acceptable ranges may indicate invalid test results.

ASSAY PROCEDURE

1. Reagents from different kit lot numbers should not be combined or interchanged. Make sure that there are no air bubbles in any reagents, calibrator and control vials.

2. Reagent Preparation

2.1 Remove reagent cartridges from packaging and replace the solid caps with the provided soft caps for ECL100. For ECL25, carefully remove the aluminum foil seal on each container on the cartridges and insert soft caps.

2.2 For the ECL100, take out the Magnetic Particle bottle make sure to roll between hands and gently but thoroughly mix until the magnetic particle solution is homogenous. The solution should be uniform with no clumps of magnetic particles visible; this step is vital for assay performance. For ECL25, mix the magnetic beads by moving back and forth the bottom part of the cartridge at upright position. Make sure to look inside the cartridge until the solution is uniform with no clumps of magnetic particles visible and no air bubbles. Recap the bottle. Open the top soft cap of all reagent bottles, leaving only the hollow soft rubber. The reagents are now ready to be loaded into the ECL100 or ECL 25 for calibration.

3. Assay Program

The following table illustrates the protocol used by the ECL100 or ECL25 for instrument operation.

Component	Quality Control Hole (µL)	Sample Hole (µL)
CA19-9 Controls (05709-05710)	10	-
Samples	-	10
CA19-9 Magnetic Particle Solution (05701)	100	100
Incubate at 37°C for 10 minutes		
Wash the reaction cuvette 3 times with wash reagent.		
Biotin CA19-9 antibody (05702)	50	50
Acridinium ester Streptavidin (05703)	50	50
Incubate at 37°C for 10 minutes		
Wash the reaction cuvette 3 times with wash reagent.		
Trigger Solution A (P-595)	100-200	100-200
Trigger Solution B (P-595)	100-200	100-200

NOTE FOR ASSAY PROCEDURE

Reagents from different kit lot numbers should not be combined or interchanged. Make sure that there is no air bubble in any reagents, calibrator and control vials.

All the reagents in this kit are ready-to-use. Different lots of the same reagents are not inter-changeable and must not be used.

Please read the reagent instructions and equipment instructions carefully before using this kit and perform the test according to relevant requirements. When reagents are loaded, the equipment will automatically stir the magnetic particles to resuspend them. Allow the regent to mix for minimum 15 min before starting the assay program.

INTERPRETATION OF RESULTS

1. The default unit for the CA19-9 project is U/mL.
2. Due to methodological differences or antibody specificity, there may be deviations between the test results of reagents from different manufacturers. Therefore, direct comparisons should not be made to avoid false interpretation.
3. When the concentration of CA19-9 in the sample exceeds 1000U/mL, the sample can be diluted before measurement.

4. When the sample concentration of CA19-9 is lower than the detection lower limit, the test result can be reported as <0.600 U/mL. When the sample concentration is higher than the detection upper limit, it can be reported as >1000.0 U/mL.

EXPECTED VALUES

Normal reference value ≤27 U/mL.

This data is obtained from 360 healthy patients, taking the upper limit of the 95% percentile range.

Note: each Laboratory is recommended to determine and establish its own reference range with local population.

LIMITATIONS OF THE PROCEDURE

1. This product is for use on the ECL100 Immunoassay Analyzer or ECL 25 Immunoassay Analyzer only. Refer to the appropriate system manuals and/or Help system for a specific description of installation, start-up, operation, system performance, instructions, calibration, precautions, hazards, maintenance, and troubleshooting.
2. Reagents from different kit lot numbers should not be combined or interchanged.
3. Test results obtained from the proposed kit should not be served as a sole basis for clinical diagnosis or patient management.
4. If the test sample result is higher than the upper limit of the calibration curve, it is recommended to re-measure after dilution according to a certain ratio. The measured value is recalculated according to the dilution ratio to ensure the accuracy of the result.

PERFORMANCE CHARACTERISTICS

1. Hook Effect:
   - The assay showed no hook effect up to 500000U/mL.
2. Limit of Detection (LoD):
   - ≤0.600 U/mL.
3. Linearity:
   - 0.600 U/mL to 1000.0U/mL,
   - linearity correlation coefficient R ≥0.990.
4. Accuracy:
   - relative deviation within ±10%.
5. Precision:
   - Intra-assay repeatability: CV≤10%
   - Inter-assay reproducibility: CV≤15%.

NOTES

1. Read the instructions carefully and gently mix the reagent well before use. Avoid any air bubble before loading the reagents onto the equipment.
2. Keep the reagent in storage condition as indicated in this IFU and on the reagent label. Do not freeze reagents.
3. Avoid contact with skin, eyes and mucous membrane, and flush the contact area with clean water immediately.
4. All patient samples must be treated as potential infectious material.
5. Components in different kits cannot be mixed.
6. All waste must be disposed complying with local regulations and laws

WARRANTY

This product is warranted to perform as described in its labeling and literature when used in accordance with all instructions. Epitope Biotechnology Co,Ltd and its distributors DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, and in no event shall Epitope Biotechnology Co,Ltd.. be liable for consequential damages. Replacement of the product or refund of the purchase price is the exclusive remedy for the purchaser. This warranty gives you specific legal rights and you may have other rights, which vary from state to state.

REFERENCE

1. Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 1979;5:957-972.
2. Stieber P, Fateh-Moghadam A. Sensible Use of Tumormarkers. Dtsch: Tumormaker und ihrsinnvollerEinsatz. ISBN 3-926725-07-9 dtsch/engl.Juergen Hartmann VerlagMarloffstein-Rathsberg (1993).
3. Herlyn M, Sears HF, Steplewski Z, et al. Monoclonal antibody detection of a circulating tumor-associated antigen. Presence of antigen in sera of patients with colorectal, gastric and pancreatic carcinoma. J ClinImmunol 1982;2:135-140.
4. Ritts RE Jr, Del Villano BC, Go VLV, et al. Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank.Int J Cancer 1984;33:339-345.
5. Farini R, Fabris C, Bonvicini P, et al. CA 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis. Eur J Cancer ClinOncol 1985;21:429-432.
6. Safi F, Roscher R, Beger HG. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma. Bull Cancer Paris 1990;77(1):83-91.

TECHNICAL ASSISTANCE AND CUSTOMER SERVICE

For technical assistance or to place an order, please contact Epitope Diagnostics, Inc. in USA at +1 858-693-7877 or email to cs@epitopediagnostics.com

Epitope Biotechnology, Co.,Ltd.
599 Yazhong Rd. 3-4F, Jiaxing
Zhejiang 314006, China

This product is marketed by
Epitope Diagnostics, Inc.
7110 Carroll Rd
San Diego, CA 92121 United States
www.epitopediagnotics.com

EC REP
MDSS GmbH
Schiffgraben 41,
30175 Hannover, Germany

GLOSSARY OF SYMBOLS (EN 980/ISO 15223)

IVD In Vitro Diagnostic Device	CE European Conformity	LOT Lot Number
REF Catalog Number	 Read Instructions before Use	 Number of Tests
 Store at	 Use by	 Keep Away from Heat and Direct Sun light
 Manufacturer	EC REP Authorized Representative in Europe	 Distributor